Predict your next investment

LENTECHS company logo
HEALTHCARE | Medical Devices & Equipment

See what CB Insights has to offer


Other Investors | Alive


LENTECHS is a clinical-stage ophthalmic medical device company. The company focuses on developing soft contact lenses. It is based in Columbus, Ohio.

LENTECHS Headquarter Location

7720 Rivers Edge Drive Suite 101

Columbus, Ohio, 43235,

United States

Latest LENTECHS News

Lentechs Enrolls First Patients in Two Clinical Trials

Jul 21, 2021

Lentechs Enrolls First Patients in Two Clinical Trials Trials will determine efficacy of investigational contact lenses for presbyopia, astigmatism, and presbyopia with astigmatism. PR Newswire07.21.21 Lentechs , a clinical-stage ophthalmic medical device company developing a new generation of soft, suspended contact lens, designed to transform the treatment paradigm for presbyopia, has enrolled the first patients in its milestone clinical trials LEN101 and LEN102 and fit with its investigational contact lens APIOC (pronunciation: AP•EE•OCK). Presbyopia is a natural part of aging characterized by a gradual loss of the eyes' ability to focus on objects up close.1 This clinical progress furthers the company's mission of reimagining vision for the 120 million people in the United States and 2 billion worldwide who have presbyopia and are faced with correction options that force a visual compromise, leading most to choose glasses over a preference for contact lenses.2,3 APIOC employs a mechanism of action like no other soft contact lens. APIOC's breakthrough design leverages a unique, anatomically inspired feature that allows for free eye movement behind a rotationally stable lens. With the lens suspended from behind the upper eyelid, APIOC is designed to allow a wearer to adjust their gaze by moving their eyes up and down behind the lens, for exceptional vision correction at all distances. It is the result of a long-term collaboration between Melissa D. Bailey, OD, Ph.D., and Joseph T. Barr, OD, MS, two of the co-founders of Lentechs. "Enrolling patients in our two milestone clinical trials for APIOC is a tremendous achievement for the Lentechs team," said President and CEO Robin G. Sears. "It marks a culmination of research and development efforts as we've worked to engineer and optimize a completely new generation of soft, suspended contact lens, launching first for presbyopia, with additional solutions for single vision correction soon to follow. Simultaneously, we are focused on preparing our team for the commercial launch of APIOC in select U.S. markets in early 2022. "    Lentechs board member and former global president, Vision Care, for Bausch and Lomb and former Johnson & Johnson Vision executive Peter Valenti added, "APIOC is a potential game-changer for optometrists and patients. The presbyopia segment offers an enormous opportunity to improve patient satisfaction and drive business growth for Eyecare Professionals (ECPs). "    While not a requirement for regulatory approval, the two clinical trials will deliver visual acuity and comfort data to ECPs in an effort to instill confidence in prescribing a new brand of soft contact lens. LEN101 aims to show how APIOC's unique mechanism of action will help ECPs bridge the gap between the 70 percent of people with presbyopia that wish to wear contact lenses and the 14-percent who actually do.3,4 The clinical trials are scheduled to be completed by the end of June. Lentechs LLC is a privately held, clinical-stage ophthalmic medical device company, focused on developing a new generation of soft, suspended contact lens. Headquartered in Columbus, Ohio, Lentechs is backed by a network of investors who are truly committed to revolutionary innovation in contact lenses. References

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.